Acura Pharmaceuticals, Inc. (ACUR) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ACUR steht fuer Acura Pharmaceuticals, Inc., ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Bewertet mit 48/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 16. März 2026Acura Pharmaceuticals, Inc. (ACUR) Gesundheitswesen & Pipeline-Uebersicht
Acura Pharmaceuticals, Inc. is a drug delivery company focused on developing and commercializing technologies for safer medication use, particularly in pain management and nasal decongestion. Its product portfolio includes Oxaydo and Nexafed, with ongoing research into abuse-deterrent formulations and collaborative agreements for global market expansion.
Investmentthese
Acura Pharmaceuticals, Inc. presents a focused investment opportunity within the specialty pharmaceutical sector. The company's commitment to developing abuse-deterrent formulations addresses a critical need in pain management. Key value drivers include the potential for increased adoption of Oxaydo and Nexafed products, coupled with successful development and commercialization of its pipeline products, including LTX-03. The company's gross margin of 94.2% indicates strong pricing power. However, the company's negative profit margin of -56.2% and negative free cash flow of $-0.00B highlight the need for improved financial performance. Upcoming catalysts include potential regulatory approvals for new formulations and expansion of existing product lines. Potential risks include competition from established pharmaceutical companies and challenges in securing additional funding for research and development.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Gross Margin of 94.2% indicates strong pricing power in its product offerings.
- Negative Profit Margin of -56.2% reflects ongoing investments in research and development and commercialization efforts.
- Free Cash Flow of $-0.00B indicates the company is currently reliant on external funding.
- Beta of -54.49 suggests the stock price is inversely correlated with the market.
- The company has six additional opioid products in various stages of formulation development, signaling future growth potential.
Wettbewerber & Vergleichsunternehmen
Staerken
- Proprietary abuse-deterrent drug delivery technologies.
- Established partnerships with other pharmaceutical companies.
- Focus on a growing market segment (abuse-deterrent formulations).
- High gross margin (94.2%).
Schwaechen
- Negative profit margin (-56.2%).
- Negative free cash flow.
- Small number of employees (9).
- Limited product portfolio.
Katalysatoren
- Upcoming: Potential regulatory approval for new abuse-deterrent formulations.
- Upcoming: Expansion of existing product lines into new markets.
- Ongoing: Research and development of new drug delivery technologies.
- Ongoing: Strategic partnerships with other pharmaceutical companies.
- Ongoing: Efforts to increase market share for Oxaydo and Nexafed.
Risiken
- Potential: Competition from larger pharmaceutical companies with greater resources.
- Potential: Regulatory changes impacting opioid prescriptions and abuse-deterrent formulations.
- Potential: Challenges in securing funding for research and development.
- Ongoing: Dependence on key partnerships for product development and commercialization.
- Ongoing: Limited liquidity due to trading on the OTC market.
Wachstumschancen
- Expansion of Oxaydo Market Share: Acura has the opportunity to increase the market share of Oxaydo, its abuse-deterrent opioid, by targeting specific patient populations and expanding its distribution network. The market for abuse-deterrent opioids is growing due to increasing awareness of opioid abuse and regulatory initiatives promoting safer pain management options. Success in this area could significantly boost revenue within the next 2-3 years.
- Commercialization of LTX-03: The successful development and commercialization of LTX-03, an immediate-release tablet utilizing LIMITx technology, represents a significant growth opportunity for Acura. This product aims to provide effective pain relief while minimizing the risk of abuse. Positive clinical trial results and regulatory approval could lead to substantial revenue generation within the next 3-5 years.
- Geographic Expansion: Acura can explore opportunities to expand its geographic reach by partnering with international distributors or establishing a direct presence in key markets. The global market for pain management and nasal decongestant products is substantial, and expanding into new regions could drive significant revenue growth over the next 5 years.
- Development of New Abuse-Deterrent Formulations: Acura's expertise in drug delivery technology positions it to develop new abuse-deterrent formulations for other commonly abused medications. This could involve partnering with other pharmaceutical companies or developing its own proprietary products. Successful development and commercialization of new formulations could create new revenue streams within the next 3-5 years.
- Strategic Partnerships and Acquisitions: Acura can pursue strategic partnerships or acquisitions to expand its product portfolio and market reach. This could involve acquiring companies with complementary technologies or products, or partnering with larger pharmaceutical companies to co-develop and commercialize new medications. Such partnerships could accelerate growth and diversify revenue streams over the next 2-5 years.
Chancen
- Expansion of Oxaydo market share.
- Commercialization of LTX-03.
- Geographic expansion.
- Development of new abuse-deterrent formulations.
Risiken
- Competition from larger pharmaceutical companies.
- Regulatory changes impacting opioid prescriptions.
- Challenges in securing funding for research and development.
- Potential product liability claims.
Wettbewerbsvorteile
- Proprietary drug delivery technologies that enhance medication safety.
- Patents protecting its formulations and technologies.
- Established partnerships with other pharmaceutical companies.
- Expertise in developing abuse-deterrent formulations.
Ueber ACUR
Acura Pharmaceuticals, Inc., established in 1935 and headquartered in Palatine, Illinois, is dedicated to the research, development, and commercialization of pharmaceutical products designed to improve medication safety. The company's primary focus is on creating innovative drug delivery technologies that address the challenges associated with prescription drug abuse and misuse. Acura's product portfolio includes Oxaydo, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain. Additionally, the company offers Nexafed products, which are pseudoephedrine and acetaminophen tablets used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy medications. Acura Pharmaceuticals operates through strategic collaboration and license agreements with companies like Egalet US, Inc., Egalet Ltd., and Abuse Deterrent Pharma, LLC. These partnerships enable Acura to manufacture, commercialize, and further develop its product offerings, including LTX-03, an immediate-release tablet utilizing LIMITx technology. With a lean team of 9 employees, Acura Pharmaceuticals continues to innovate in the drug delivery space, aiming to provide safer and more effective medication options.
Was das Unternehmen tut
- Develops and commercializes pharmaceutical products.
- Focuses on abuse-deterrent drug delivery technologies.
- Offers Oxaydo tablets for pain management.
- Provides Nexafed products for nasal decongestion.
- Engages in research and development of new formulations.
- Collaborates with other pharmaceutical companies for product development and commercialization.
Geschaeftsmodell
- Develops and patents proprietary drug delivery technologies.
- Manufactures and sells pharmaceutical products through partnerships and direct sales.
- Generates revenue through product sales and licensing agreements.
- Invests in research and development to expand its product pipeline.
Branchenkontext
Acura Pharmaceuticals, Inc. operates within the specialty pharmaceutical industry, which is characterized by a focus on developing niche products and innovative drug delivery systems. The industry is driven by the need for safer and more effective medications, particularly in areas such as pain management and abuse deterrence. The competitive landscape includes both large pharmaceutical companies and smaller, specialized firms. Acura's focus on abuse-deterrent formulations positions it within a growing segment of the market, driven by increasing concerns about opioid abuse and regulatory pressures to develop safer alternatives. The global pharmaceutical market is projected to reach trillions of dollars by 2026, with specialty pharmaceuticals representing a significant portion of this growth.
Wichtige Kunden
- Patients suffering from acute and chronic pain.
- Individuals seeking relief from nasal congestion.
- Pharmaceutical companies seeking to incorporate abuse-deterrent technologies into their products.
- Distributors and wholesalers of pharmaceutical products.
Finanzdaten
Chart & Info
Acura Pharmaceuticals, Inc. (ACUR) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Highs On Tuesday
· 5. Nov. 2019
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer ACUR.
Kursziele
Wall-Street-Kurszielanalyse fuer ACUR.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von ACUR auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Robert Jones
CEO
Robert Jones serves as the CEO of Acura Pharmaceuticals, Inc., leading a team of 9 employees. Information regarding his detailed career history, education, and previous roles is not available in the provided source data. Therefore, a comprehensive background summary cannot be provided at this time.
Erfolgsbilanz: Due to the limited information available in the provided source data, a detailed track record of Robert Jones' key achievements, strategic decisions, and company milestones under his leadership cannot be accurately assessed.
ACUR OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Acura Pharmaceuticals, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited liquidity, price volatility, and lack of transparency compared to exchange-listed stocks.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited liquidity due to low trading volume on the OTC market.
- Higher price volatility compared to exchange-listed stocks.
- Potential for limited or inconsistent financial disclosures.
- Increased risk of fraud or manipulation due to less regulatory oversight.
- Difficulty in obtaining accurate and timely information about the company.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their experience.
- Research the company's products and market position.
- Evaluate the company's capital structure and debt levels.
- Determine the company's compliance with regulatory requirements.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- The company has been incorporated since 1935, indicating a long operating history.
- Acura Pharmaceuticals, Inc. has existing commercialized products (Oxaydo and Nexafed).
- The company has collaboration and license agreements with other pharmaceutical companies.
- Acura Pharmaceuticals, Inc. is focused on developing abuse-deterrent formulations, addressing a significant public health concern.
- The company has a team of employees, suggesting ongoing operations.
Was Anleger ueber Acura Pharmaceuticals, Inc. (ACUR) wissen wollen
What are the key factors to evaluate for ACUR?
Acura Pharmaceuticals, Inc. (ACUR) currently holds an AI score of 48/100, indicating low score. Key strength: Proprietary abuse-deterrent drug delivery technologies.. Primary risk to monitor: Potential: Competition from larger pharmaceutical companies with greater resources.. This is not financial advice.
How frequently does ACUR data refresh on this page?
ACUR prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ACUR's recent stock price performance?
Recent price movement in Acura Pharmaceuticals, Inc. (ACUR) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary abuse-deterrent drug delivery technologies.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ACUR overvalued or undervalued right now?
Determining whether Acura Pharmaceuticals, Inc. (ACUR) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ACUR?
Before investing in Acura Pharmaceuticals, Inc. (ACUR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ACUR to a portfolio?
Potential reasons to consider Acura Pharmaceuticals, Inc. (ACUR) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary abuse-deterrent drug delivery technologies.. Additionally: Established partnerships with other pharmaceutical companies.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of ACUR?
Yes, most major brokerages offer fractional shares of Acura Pharmaceuticals, Inc. (ACUR) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ACUR's earnings and financial reports?
Acura Pharmaceuticals, Inc. (ACUR) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for ACUR earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data as of 2026-03-16.
- OTC market data may be less reliable than exchange-listed data.
- AI analysis is pending and may provide additional insights in the future.